secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2026-06-24T21:02:19+00:00
Accession:  0001193125-26-281246
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica raises ~$15M in private placement; FDA clears continued Auxora development
--------------------------------------------------------------------------------

- Private placement of 18.7M units at $0.8033 each; gross proceeds ~$15M, up to $34M additional from warrant exercises.
- FDA reviewed KOURAGE trial protocol amendment and interim safety data; no comments or questions, dosing may resume.
- Insiders including CEO, CBO, CMO, and major holders purchase ~6.9M units.
- Plans Phase 1b study of Auxora in pulmonary arterial hypertension (PAH) with data expected mid-2027.
- IND clearance for oral CM5480 anticipated mid-2027; cash runway into second half of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312526281246/0001193125-26-281246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312526281246/d142943d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-281246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer